Conditions: Non-Small Cell Lung Cancer
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 260
Healthy volunteers: no

Brief summary:
The purpose of this study is to compare the combination of pemetrexed and carboplatin with the combination of docetaxel and carboplatin in terms of survival without Grade 3 or 4 toxicity in previously untreated patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).

Detailed description:

Arms:
arm 1: Drug: pemetrexed 500 milligrams per square meter (mg/m\^2), intravenous (IV), every (q) 21 days x 6 cycles maximum

Drug: carboplatin Area Under the Curve (AUC) 5 milligram\*minute/milliLiter (mg\*min/mL), IV, q 21 days x 6 cycles maximum arm 2: Drug: docetaxel 75 mg/m\^2, IV, q 21 days x 6 cycles maximum

Drug: carboplatin AUC 5 mg\*min/mL, IV, q 21 days x 6 cycles maximum

Interventions: intervention 1: pemetrexed intervention 2: docetaxel intervention 3: carboplatin
Intervention descriptions: intervention 1: 500 mg/m\^2, IV, q 21 days x 6 cycles maximum intervention 2: 75 mg/m\^2, IV, q 21 days x 6 cycles maximum intervention 3: AUC 5 mg\*min/mL, IV, q 21 days x 6 cycles maximum

Protocol document: